ACT AlzChem Group

DGAP-News: AlzChem Group AG increases sales in the first quarter of 2020 by 2.8% to EUR 94.7 million

DGAP-News: AlzChem Group AG / Key word(s): Quarterly / Interim Statement
AlzChem Group AG increases sales in the first quarter of 2020 by 2.8% to EUR 94.7 million

12.05.2020 / 06:58
The issuer is solely responsible for the content of this announcement.


AlzChem Group AG increases sales in the first quarter of 2020 by 2.8% to EUR 94.7 million

- EBITDA at forecast level of EUR 12.3 million

- Full-year forecast for 2020 still valid

Trostberg, May 12, 2020 - AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, recorded a pleasing first quarter of 2020. Due to the traditionally highly diversified product portfolio, the economic effects of the COVID-19 pandemic were almost completely compensated for. Accordingly, Group sales in the first three months of 2020 improved by 2.8% from EUR 92.1 million to EUR 94.7 million. In the Specialty Chemicals segment, the expected very strong growth of Creamino(R) was successfully realized. In addition, demand for BioSelect(R) products also rose significantly, as these are an essential component of the COVID-19 test kits, among other things. The fact that sales of the specialty product Dormex(R) did not quite match the previous year's level was due entirely to postponed deliveries until the second quarter of 2020. In the Basics & Intermediates segment, the effects from the steel and automotive sectors were offset by the generally encouraging performance of the NITRALZ(R) product range and basic chemicals. In addition, Perlka(R) sales volumes were higher than in the previous year, as additional areas of application and sales regions were developed.

On the earnings side, consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) developed at the forecast level of EUR 12.3 million (first quarter 2019: EUR 13.2 million). The resulting EBITDA margin was 13.0% after 14.4% in the prior-year quarter. This development was driven by previously forecast increases in personnel costs, expenses in connection with the market launches of the Creapure(R) derivatives LIVADUR(R) and Your Encour!TM, as well as the decline in volumes in the automotive sector. This was offset by developments on the procurement side, where certain raw material and electricity prices in Germany and Sweden showed a downward trend in the reporting period. Consolidated result for the period amounted to EUR 4.4 million in the first quarter of 2020 (first quarter of 2019: EUR 5.6 million).

Based on the positive business development in the first quarter of 2020, the Management Board is maintaining its forecast for the full year 2020. Among other things, a slight to sharp organic rise in Group sales is expected, as well as adjusted EBITDA at least at the previous year's level to - parallel to sales - a sharp rise.

The detailed quarterly statement for the first quarter of 2020 is available for download on the website under Investor Relations/Publications/Financial Reports.

About AlzChem
The AlzChem Group is a vertically integrated manufacturer of chemical products based on the so-called NCN chain. These are products with typical nitrogen-carbon-nitrogen bonding that are used in a wide variety of different industries. The Group has a leading position in select niche markets. The strategic focus of growth and the main focus of its extensive research and development are on the business segment Specialty Chemicals. The company has around 1,620 employees at four sites in Germany and three other sites abroad.



12.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: AlzChem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1041791

 
End of News DGAP News Service

1041791  12.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1041791&application_name=news&site_id=research_pool
EN
12/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlzChem Group

Peter Thilo Hasler
  • Peter Thilo Hasler

Zum Halbjahr neue Höchstwerte bei Umsatz und Marge

Während das Basissegment Basics & Intermediates erwartungsgemäß rückläufig war (H1/2025 Umsatz EUR 78,2 Mio., -14,2% YoY), verzeichnete das margenträchtige Segment Specialty Chemicals im ersten Halbjahr 2025 ein Umsatzplus von 8,9% auf EUR 194,6 Mio. – getragen von einem Nachfrageaufschwung im Bereich Custom Manufacturing sowie einem weiterhin starken Geschäft mit Creapure im Bereich Human Nutrition. Der Umsatzanteil des Segments liegt mittlerweile bei 67,7% – Tendenz steigend und ist damit nach...

Peter Thilo Hasler
  • Peter Thilo Hasler

Weiterhin mit robustem Gewinnwachstum

Nach wie vor ist die Ertragsentwicklung von Alzchem von konjunkturellen Herausforderungen geprägt, profitiert aber in ungleich stärkerem Maße von der Verschiebung des Umsatz-Mix in das hochmargige Segment Specialty Chemicals. Weil deshalb die vorgelegten Zahlen zum ersten Quartal 2025 erneut über unseren Schätzungen sowie den Consensus-Erwartungen lagen und wir davon ausgehen, dass die höhermargigen Potenziale weiterhin abgeschöpft werden können, heben wir unser aus einem dreiphasigen DCF-Entity...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung...

EQS-News: Alzchem Group AG / Schlagwort(e): Aktienrückkauf/Aktienrückkauf Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052 - Zeitweilige Unterbrechung des Aktienrückkaufprogramms 17.03.2025 / 11:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Alzchem Group AG   Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052       Trostberg, 17. März 2025   Zeitweilige Unterbrechung de...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the ...

EQS-News: Alzchem Group AG / Key word(s): Share Buyback/Share Buyback Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - Temporary Interruption of Share Repurchase Prog 17.03.2025 / 11:38 CET/CEST The issuer is solely responsible for the content of this announcement. Alzchem Group AG   Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, March 17, 2025   Temporary Inter...

Peter Thilo Hasler
  • Peter Thilo Hasler

Von hohem Niveau aus weiter aufwärts

Dass Alzchem auch im vierten Quartal 2024 sowohl die eigene Guidance als auch alle Consensus-Prognosen übertraf, kann aus unserer Sicht nicht als Normalität eingestuft werden. Kritisch ließe sich einwenden, dass die Luft angesichts des inzwischen erreichten Margenniveaus dünner wird, doch lässt die anhaltende Verschiebung zum höhermargigen Segment Specialty Chemicals nach unserer Auffassung einen erneuten Margenanstieg und einen damit einhergehenden überproportionalen Ergebnisanstieg auch im Ges...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch